93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy D.R. Spigel,S. Peters,M-J. Ahn,M. Tsuboi,J. Chaft, D. Harpole, F. Barlesi,C. Abbosh, H. Mann,R. May, P.A. Dennis,C. SwantonJournal of Thoracic Oncology（2021）引用 25|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
